Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMC-3G3 · 1 trial · 1 indication
After all patients complete a cohort, toxicity data is reviewed before the next cohort of patients is treated at the next higher dose level
| Arm | Type | Description |
|---|---|---|
| IMC-3G3 | EXPERIMENTAL | All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into. |
| Name | Type | Description |
|---|---|---|
| IMC-3G3 | BIOLOGICAL | Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week. |
Inclusion Criteria: 1. Histopathological-documented, measurable, or non measurable, advanced primary tumor or recurrent solid tumor or lymphoma unresponsive to standard therapy or for which there is no standard therapy available. 2. Eastern Cooperative Oncology Group (ECOG) performance status score...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IMC-3G3 is an investigational monoclonal antibody being developed for the treatment of solid tumors. It is intended for patients whose tumors are not responding to standard therapies or for whom no standard therapy is available. The drug is currently in Phase 1 clinical development.
IMC-3G3 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational monoclonal antibody in patients with solid tumors.
IMC-3G3 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial has been completed, and the drug remains under investigation for the treatment of solid tumors.
IMC-3G3 has been studied in one clinical trial with the identifier NCT00768391. This Phase 1 trial, titled 'Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available,' enrolled 20 participants with solid tumors in the United States. The trial has been completed.
IMC-3G3 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial evaluated the drug in 20 patients with solid tumors, but further clinical studies would be needed to establish safety and efficacy before any regulatory approval could be considered.